Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Efpeglenatide has proven to significantly reduce several risk factors for cardiovascular and kidney disease.
Read More »Efpeglenatide Has Cardiovascular and Renal Benefit Outcomes in Type 2 Diabetes
Canagliflozin’s Renal and Cardiovascular Benefits in People with Heart Failure
CREDENCE trial shows that canagliflozin, an SGLT2 inhibitor, lowers the risk of cardiovascular and renal events in patients with T2DM, regardless of prior history of heart failure.
Read More »An Update on the Benefits of GLP-1 Receptor Agonists for Type 2 Diabetes
GLP-1 receptor agonists are a pharmacologic treatment of type 2 diabetes with potential cardiorenal benefits.
Read More »The Human and Economic Burden of Diabetes and Its Comorbidities
Every comorbidity related to diabetes causes life expectancy to plummet and medical costs to soar.
Read More »Using Dapagliflozin for Reduction in Adverse Renal and CV Outcomes
Patients had significant reduction in urinary albumin-to-creatinine ratio (UACR) in the first six months of using dapagliflozin.
Read More »Don’t Forget our Patients with Type 1 Diabetes
Cardiovascular and renal disease burdens also occur in type 1 diabetes.
Read More »ADA 81st Symposium: Evidence-Based Guidelines For Diabetes and Chronic Kidney Disease
Diabetes is the leading cause of chronic kidney disease due to microvascular damage to the renal blood vessels.
Read More »ADA 2021: Finerenone in the Chronic Kidney Disease and Diabetes Population
Finerenone is a mineralocorticoid receptor antagonist indicated for chronic kidney disease (CKD) with type 2 diabetes. Does the use of insulin affect its performance against kidney and cardiovascular issues?
Read More »ADA 81st Symposium: Cardiovascular and Kidney Outcomes in Efpeglenatide
With the introduction of this glucagon-like peptide-1 receptor agonist (GLP-1 RA), efpeglenatide, could we see new cardiovascular and renal benefits for patients with type 2 diabetes?
Read More »Cardiovascular and Kidney Outcomes when Discontinuing SGLT-2 Inhibitor
After starting SGLT-2i, is the discontinuation of therapy necessary if there is an immediate decline in estimated Glomerular Filtration Rate (eGFR) in patients?
Read More »